Molecular Perspective on Pancreatic Cancers with a Focus on Genetics, Genomics, and Diagnostics

Şeyda Kaya; Mustafa Murat Öztürk; Dilek Arslan Ateşşahin; İnanç Baral; Sevgi Durna Daştan

doi:10.17776/csj.1854954

Molecular Perspective on Pancreatic Cancers with a Focus on Genetics, Genomics, and Diagnostics

Abstract

The pancreas stands out as a complicated organ vital for maintaining physiological balance with its exocrine and endocrine roles. It is aimed to present the genetic underpinnings of working basis of pancreas and its diseases with related biochemical pathways, especially with a focus on pancreatic cancers (PC). This article collects all current research and filters data about pancreatic biology and the molecular genetic backgrounds, and genomics pathways related pancreatic diseases. The pancreas has the highest number of different genetic disorders, which are always multifactorial. The pancreatic adenocarcinoma are particularly significant due to their rapid metastatic potential, extreme lethality, and surprising mortality rates. Various studies have revealed the different causes of the development of pancreatic cancers. And it is seen that it may be both a somatic and hereditary type of cancer. Some very important research has emphasised a substantial but insufficient network of gene-phenotype relationships for several mutations and susceptibility loci. This article collects the detailed perspective about existing literature to underline the molecular view of pancreatic cancers based on genetic, genomic and diagnostic principles. This article focus on isolated aspects such as genomics or diagnostics, this review provides an integrated perspective combining molecular genetics, genomic instability, and emerging diagnostic approaches. By synthesizing findings across multiple disciplines, this study highlights the importance of a systems-level understanding of pancreatic cancer and proposes a framework for future research directions.

Keywords

Adenocarcinoma, Cancer, Inheritance, Mutation, Pancreas

References

Young, B. (2006). Wheater’s functional histology: A text and colour atlas (5th ed.). Churchill Livingstone/Elsevier.
Sakorafas, G. H., Pappa, I., & Smyrniotis, V. (2010). Pancreatic cancer: Molecular genetics and clinical applications. In eLS. https://doi.org/10.1002/9780470015902.a0006057.pub2
Blum, R., & Kloog, Y. (2014). Metabolism addiction in pancreatic cancer. Cell Death & Disease, 5(2), e1065. https://doi.org/10.1038/cddis.2014.38
Udupa, S., Nguyen, S., Hoang, G., Nguyen, T., Quinones, A., Pham, K., & Le, A. (2019). Upregulation of the glutaminase II pathway contributes to glutamate production upon glutaminase 1 inhibition in pancreatic cancer. Proteomics, 19(21–22). https://doi.org/10.1002/pmic.201800451
Chaika, N., Yu, F., Purohit, V., Mehla, K., Lazenby, A., DiMaio, D., & Singh, P. (2012). Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. PLoS ONE, 7(3), e32996. https://doi.org/10.1371/journal.pone.0032996
Gukovskaya, A., & Gukovsky, I. (2012). Autophagy and pancreatitis. American Journal of Physiology-Gastrointestinal and Liver Physiology, 303(9), G993–G1003. https://doi.org/10.1152/ajpgi.00122.2012
Oliver-Krasinski, J., & Stoffers, D. (2008). On the origin of the β cell. Genes & Development, 22(15), 1998–2021. https://doi.org/10.1101/gad.1670808
Online Mendelian Inheritance in Man. (2024, April 11). OMIM. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University. https://omim.org/
Online Mendelian Inheritance in Man. (2023, January 21). MIM Number: 260350. Johns Hopkins University. https://omim.org/
Amundadottir, L., Kraft, P., Stolzenberg-Solomon, R. Z., Fuchs, C. S., Petersen, G. M., Arslan, A. A., Bueno-de-Mesquita, H. B., Gross, M., Helzlsouer, K., Jacobs, E. J., LaCroix, A., Zheng, W., Albanes, D., Bamlet, W., Berg, C. D., Berrino, F., Bingham, S., Buring, E. J., Bracci, P. M., Canzian, F., & Hoover, R. N. (2009). Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nature Genetics, 41(9), 986–990. https://doi.org/10.1038/ng.429

Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008). Cancer statistics, 2008. CA: A Cancer Journal for Clinicians, 58(2), 71–96. https://doi.org/10.3322/CA.2007.0010
Hartmann, D., & Friess, H. (2017). Adenocarcinomas. In Reference Module in Life Sciences. Elsevier. https://doi.org/10.1016/B978-0-12-809633-8.06013-1
Evans, J. P., Burke, W., Chen, R., Bennett, R. L., Schmidt, R. A., Dellinger, E. P., Kimmey, M., Crispin, D., Brentnall, T. A., & Byrd, D. R. (1995). Familial pancreatic adenocarcinoma: Association with diabetes and early molecular diagnosis. Journal of Medical Genetics, 32(5), 330–335. https://doi.org/10.1136/jmg.32.5.330
Banke, M. G., Mulvihill, J. J., & Aston, E. C. (2000). Inheritance of pancreatic cancer in pancreatic cancer-prone families. Medical Clinics of North America, 84(3), 677–689. https://doi.org/10.1016/s0025-7125(05)70250-9
Brand, R. E., & Lynch, H. T. (2000). Hereditary pancreatic adenocarcinoma: A clinical perspective. Medical Clinics of North America, 84(3), 665–675. https://doi.org/10.1016/s0025-7125(05)70249-2
Klein, A. P., Beaty, T. H., Bailey-Wilson, J. E., Brune, K. A., Hruban, R. H., & Petersen, G. M. (2002). Evidence for a major gene influencing risk of pancreatic cancer. Genetic Epidemiology, 23(2), 133–149. https://doi.org/10.1002/gepi.1102
Brand, R. E., & Lynch, H. T. (2006). Genotype/phenotype of familial pancreatic cancer. Endocrinology and Metabolism Clinics of North America, 35(2), 405–418. https://doi.org/10.1016/j.ecl.2006.02.015
McWilliams, R. R., Rabe, K. G., Olswold, C., De Andrade, M., & Petersen, G. M. (2005). Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer, 104(2), 388–394. https://doi.org/10.1002/cncr.21166
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005). RAS is regulated by the let-7 microRNA family. Cell, 120(5), 635–647. https://doi.org/10.1016/j.cell.2005.01.014
Popescu, N. C., Amsbaugh, S. C., DiPaolo, J. A., Tronick, S. R., Aaronson, S. A., & Swan, D. C. (1985). Chromosomal localization of three human RAS genes by in situ molecular hybridization. Somatic Cell and Molecular Genetics, 11(2), 149–155. https://doi.org/10.1007/BF01534703
Tereba, A. (1985). Chromosomal localization of protooncogenes. International Review of Cytology, 95, 1–43. https://doi.org/10.1016/s0074-7696(08)60577-x
Carta, C., Pantaleoni, F., Bocchinfuso, G., Stella, L., Vasta, I., Sarkozy, A., Digilio, C., Palleschi, A., Pizzuti, A., Grammatico, P., Zampino, G., Dallapiccola, B., Gelb, B. D., & Tartaglia, M. (2006). Germline missense mutations affecting KRAS isoform B are associated with a severe Noonan syndrome phenotype. The American Journal of Human Genetics, 79(1), 129–135. https://doi.org/10.1086/504394
Tsai, F. D., Lopes, M. S., Zhou, M., Court, H., Ponce, O., Fiordalisi, J. J., Gierut, J. J., Cox, A. D., Haigis, K. M., & Philips, M. R. (2015). K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif. Proceedings of the National Academy of Sciences, 112(3), 779–784. https://doi.org/10.1073/pnas.1412811112
Kranenburg, O. (2005). The KRAS oncogene: Past, present, and future. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1756(2), 81–82. https://doi.org/10.1016/j.bbcan.2005.10.001
Hruban, R. H., Goggins, M., Parsons, J., & Kern, S. E. (2000). Progression model for pancreatic cancer. Clinical Cancer Research, 6(8), 2969–2972.
Su, G. H., Bansal, R., Murphy, K. M., Montgomery, E., Yeo, C. J., Hruban, R. H., & Kern, S. E. (2001). ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proceedings of the National Academy of Sciences, 98(6), 3254–3257. https://doi.org/10.1073/pnas.051484398
Bourdon, J. C. (2007). p53 and its isoforms in cancer. British Journal of Cancer, 97(3), 277–282. https://doi.org/10.1038/sj.bjc.6603886
Bourdon, J. C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005). p53 isoforms can regulate p53 transcriptional activity. Genes & Development, 19(18), 2122–2137. https://doi.org/10.1101/gad.1339905
Cancer Genome Atlas Research Network. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455(7216), 1061–1068. https://doi.org/10.1038/nature07385
Harris, C. C. (1996). Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. Journal of the National Cancer Institute, 88(20), 1442–1455. https://doi.org/10.1093/jnci/88.20.1442
Rosenfeldt, M. T., O'Prey, J., Morton, J. P., Nixon, C., MacKay, G., Mrowinska, A., Au, A., Rai, T. S., Zheng, L., Ridgway, R., Adams, P. D., Anderson, K. I., Gottlieb, E., Sansom, O. J., & Ryan, K. M. (2013). p53 status determines the role of autophagy in pancreatic tumour development. Nature, 504(7479), 296–300. https://doi.org/10.1038/nature12865
Casey, G., Yamanaka, Y., Friess, H., Kobrin, M. S., Lopez, M. E., Buchler, M., Beger, H. G., & Korc, M. (1993). p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Letters, 69(3), 151–160. https://doi.org/10.1016/0304-3835(93)90168-9
Davis, B. N., Hilyard, A. C., Lagna, G., & Hata, A. (2008). SMAD proteins control DROSHA-mediated microRNA maturation. Nature, 454(7200), 56–61. https://doi.org/10.1038/nature07086
Hahn, S. A., Schutte, M., Hoque, A. T., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., & Kern, S. E. (1996). DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science, 271(5247), 350–353. https://doi.org/10.1126/science.271.5247.350
Qin, J., Wu, S. P., Creighton, C. J., Dai, F., Xie, X., Cheng, C. M., Frolov, A., Ayala, G., Lin, X., Feng, X. H., Ittmann, M. M., Tsai, S. J., Tsai, M. J., & Tsai, S. Y. (2013). COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature, 493(7431), 236–240. https://doi.org/10.1038/nature11674
Schutte, M., Hruban, R. H., Hedrick, L., Cho, K. R., Nadasdy, G. M., Weinstein, C. L., Bova, G. S., Isaacs, W. B., Cairns, P., Nawroz, H., Sidransky, D., Casero, R. A., Jr., Meltzer, P. S., Hahn, S. A., & Kern, S. E. (1996). DPC4 gene in various tumor types. Cancer Research, 56(11), 2527–2530.
Xu, X., Jin, D., Durgan, J., & Hall, A. (2013). LKB1 controls human bronchial epithelial morphogenesis through p114RhoGEF-dependent RhoA activation. Molecular and Cellular Biology, 33(14), 2671–2682. https://doi.org/10.1128/MCB.00154-13
Jenne, D. E., Reimann, H., Nezu, J., Friedel, W., Loff, S., Jeschke, R., Müller, O., Back, W., & Zimmer, M. (1998). Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nature Genetics, 18(1), 38–43. https://doi.org/10.1038/ng0198-38
Hemminki, A., Tomlinson, I., Markie, D., Järvinen, H., Sistonen, P., Björkqvist, A. M., Knuutila, S., Salovaara, R., Bodmer, W., Shibata, D., de la Chapelle, A., & Aaltonen, L. A. (1997). Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nature Genetics, 15(1), 87–90. https://doi.org/10.1038/ng0197-87
Su, G. H., Hruban, R. H., Bansal, R. K., Bova, G. S., Tang, D. J., Shekher, M. C., Westerman, A. M., Entius, M. M., Goggins, M., Yeo, C. J., & Kern, S. E. (1999). Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. The American Journal of Pathology, 154(6), 1835–1840. https://doi.org/10.1016/S0002-9440(10)65440-5
Hruban, R. H., Canto, M. I., & Yeo, C. J. (2001). Prevention of pancreatic cancer and strategies for management of familial pancreatic cancer. Digestive Diseases, 19(1), 76–84. https://doi.org/10.1159/000050656
Meckler, K. A., Brentnall, T. A., Haggitt, R. C., Crispin, D., Byrd, D. R., Kimmey, M. B., & Bronner, M. P. (2001). Familial fibrocystic pancreatic atrophy with endocrine cell hyperplasia and pancreatic carcinoma. The American Journal of Surgical Pathology, 25(8), 1047–1053. https://doi.org/10.1097/00000478-200108000-00009
Pogue-Geile, K. L., Chen, R., Bronner, M. P., Crnogorac-Jurcevic, T., Moyes, K. W., Dowen, S., Otey, C. A., Crispin, D. A., George, R. D., Whitcomb, D. C., & Brentnall, T. A. (2006). Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Medicine, 3(12), e516. https://doi.org/10.1371/journal.pmed.0030516
Zogopoulos, G., Rothenmund, H., Eppel, A., Ash, C., Akbari, M. R., Hedley, D., Narod, S. A., & Gallinger, S. (2007). The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. Human Genetics, 121(5), 635–637. https://doi.org/10.1007/s00439-007-0361-z
Zhen, D. B., Rabe, K. G., Gallinger, S., Syngal, S., Schwartz, A. G., Goggins, M. G., Hruban, R. H., Cote, M. L., McWilliams, R. R., Roberts, N. J., Cannon-Albright, L. A., Li, D., Moyes, K., Wenstrup, R. J., Hartman, A. R., Seminara, D., Klein, A. P., & Petersen, G. M. (2015). BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: A PACGENE study. Genetics in Medicine, 17(7), 569–577. https://doi.org/10.1038/gim.2014.153
Tavtigian, S. V., Simard, J., Rommens, J., Couch, F., Shattuck-Eidens, D., Neuhausen, S., Merajver, S., Thorlacius, S., Offit, K., Stoppa-Lyonnet, D., Belanger, C., Bell, R., Berry, S., Bogden, R., Chen, Q., Davis, T., Dumont, M., Frye, C., Hattier, T., ... & Goldgar, D. E. (1996). The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nature Genetics, 12(3), 333–337. https://doi.org/10.1038/ng0396-333
Murphy, K. M., Brune, K. A., Griffin, C., Sollenberger, J. E., Petersen, G. M., Bansal, R., Hruban, R. H., & Kern, S. E. (2002). Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17%. Cancer Research, 62(13), 3789–3793.
Yang, X., Leslie, G., Doroszuk, A., Schneider, S., Allen, J., Decker, B., Dunning, A. M., Redman, J., Scarth, J., Plaskocinska, I., Luccarini, C., Shah, M., Pooley, K., Dorling, L., Lee, A., Adank, M. A., Adlard, J., Aittomäki, K., Andrulis, I. L., ... & Tischkowitz, M. (2020). Cancer risks associated with germline PALB2 pathogenic variants: An international study of 524 families. Journal of Clinical Oncology, 38(7), 674–685. https://doi.org/10.1200/JCO.19.01907
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C., Palmisano, E., Brune, K., Jaffee, E. M., Iacobuzio-Donahue, C. A., Maitra, A., Parmigiani, G., Kern, S. E., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Eshleman, J. R., Goggins, M., & Klein, A. P. (2009). Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science, 324(5924), 217. https://doi.org/10.1126/science.1171202
Al-Sukhni, W., Rothenmund, H., Borgida, A. E., Zogopoulos, G., O'Shea, A. M., Pollett, A., & Gallinger, S. (2008). Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Human Genetics, 124(3), 271–278. https://doi.org/10.1007/s00439-008-0554-0
Nissim, S., Leshchiner, I., Mancias, J. D., Greenblatt, M. B., Maertens, O., Cassa, C. A., Rosenfeld, J. A., Cox, A. G., Hedgepeth, J., Wucherpfennig, J. I., Kim, A. J., Henderson, J. E., Gonyo, P., Brandt, A., Lorimer, E., Unger, B., Prokop, J. W., Heidel, J. R., Wang, X. X., ... & Goessling, W. (2019). Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. Nature Genetics, 51(9), 1308–1314. https://doi.org/10.1038/s41588-019-0475-y
Li, Q., Wang, L., Zeng, L., Zhang, Y., Li, K., Jin, P., Su, B., & Wang, L. (2010). Evaluation of the novel gene RABL3 in the regulation of proliferation and motility in human cancer cells. Oncology Reports, 24(2), 433–440. https://doi.org/10.3892/or_00000876
Lowenfels, A. B., Maisonneuve, P., DiMagno, E. P., Elitsur, Y., Gates, L. K., Jr., Perrault, J., & Whitcomb, D. C. (1997). Hereditary pancreatitis and the risk of pancreatic cancer. Journal of the National Cancer Institute, 89(6), 442–446. https://doi.org/10.1093/jnci/89.6.442
Petersen, G. M., Amundadottir, L., Fuchs, C. S., Kraft, P., Stolzenberg-Solomon, R. Z., Jacobs, K. B., Arslan, A. A., Bueno-de-Mesquita, H. B., Gallinger, S., Gross, M., Helzlsouer, K., Holly, E. A., Jacobs, E. J., Klein, A. P., LaCroix, A., Li, D., Mandelson, M. T., Olson, S. H., Risch, H. H., ... & Chanock, S. J. (2010). A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nature Genetics, 42(3), 224–228. https://doi.org/10.1038/ng.522
Zheng, J., Huang, X., Tan, W., Yu, D., Du, Z., Chang, J., Wei, L., Han, Y., Wang, C., Che, X., Zhou, Y., Miao, X., Jiang, G., Yu, X., Yang, X., Cao, G., Zuo, C., Li, Z., Wang, C., ... & Lin, D. (2016). Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. Nature Genetics, 48(7), 747–757. https://doi.org/10.1038/ng.3568
Ansari, D., Torén, W., Zhou, Q., Hu, D., & Andersson, R. (2019). Proteomic and genomic profiling of pancreatic cancer. Cell Biology and Toxicology, 35(4), 333–343. https://doi.org/10.1007/s10565-019-09465-9
Martinez-Bosch, N., Vinaixa, J., & Navarro, P. (2018). Immune evasion in pancreatic cancer: From mechanisms to therapy. Cancers, 10(1), 6. https://doi.org/10.3390/cancers10010006
Pelosi, E., Castelli, G., & Testa, U. (2017). Pancreatic cancer: Molecular characterization, clonal evolution and cancer stem cells. Biomedicines, 5(4), 65. https://doi.org/10.3390/biomedicines5040065
Sausen, M., Phallen, J., Adleff, V., Jones, S., Leary, R. J., Barrett, M. T., Anagnostou, V., Parpart-Li, S., Murphy, D., Kay Li, Q., Hruban, C. A., Scharpf, R., White, J. R., O'Dwyer, P. J., Allen, P. J., Eshleman, J. R., Thompson, C. B., Klimstra, D. S., Linehan, D. C., ... & Velculescu, V. E. (2015). Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nature Communications, 6, 7686. https://doi.org/10.1038/ncomms8686
Du, Y., Zhao, B., Liu, Z., Ren, X., Zhao, W., Li, Z., You, L., & Zhao, Y. (2017). Molecular subtyping of pancreatic cancer: Translating genomics and transcriptomics into the clinic. Journal of Cancer, 8(4), 513–522. https://doi.org/10.7150/jca.17622
Makohon-Moore, A., Brosnan, J. A., & Iacobuzio-Donahue, C. A. (2013). Pancreatic cancer genomics: Insights and opportunities for clinical translation. Genome Medicine, 5(3), 26. https://doi.org/10.1186/gm430
Wei, T., Zhang, J., Li, J., Chen, Q., Zhi, X., Tao, W., Ma, J., Yang, J., Lou, Y., Ma, T., Li, X., Zhang, Q., Chen, W., Que, R., Gao, S., Bai, X., & Liang, T. (2020). Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. Molecular Oncology, 14(9), 1966–1977. https://doi.org/10.1002/1878-0261.12757
Du, J., Qiu, X., Lu, C., Zhu, Y., Kong, W., Xu, M., Zhang, X., Tang, M., Chen, J., Li, Q., Li, A., He, J., Gu, Q., Wang, L., Qiu, Y., & Liu, B. (2022). Molecular landscape and prognostic biomarker analysis of advanced pancreatic cancer and predictors of treatment efficacy of AG chemotherapy. Frontiers in Oncology, 12, 844527. https://doi.org/10.3389/fonc.2022.844527
Liang, J. W., Shi, Z. Z., Shen, T. Y., Che, X., Wang, Z., Shi, S. S., Xu, X., Cai, Y., Zhao, P., Wang, C. F., Zhou, Z. X., & Wang, M. R. (2014). Identification of genomic alterations in pancreatic cancer using array-based comparative genomic hybridization. PLoS ONE, 9(12), e114616. https://doi.org/10.1371/journal.pone.0114616
Fan, Z., Xiao, Y., Du, Y., Zhang, Y., & Zhou, W. (2025). Pancreatic cancer subtyping – the keystone of precision treatment. Frontiers in Immunology, 16, 1563725. https://doi.org/10.3389/fimmu.2025.1563725
Ciernikova, S., Earl, J., García Bermejo, M. L., Stevurkova, V., Carrato, A., & Smolkova, B. (2020). Epigenetic landscape in pancreatic ductal adenocarcinoma: On the way to overcome drug resistance? International Journal of Molecular Sciences, 21(11), 4091. https://doi.org/10.3390/ijms21114091
Barrett, M. T., Deiotte, R., Lenkiewicz, E., Malasi, S., Holley, T., Evers, L., Posner, R. G., Jones, T., Han, H., Sausen, M., Velculescu, V. E., Drebin, J., O'Dwyer, P., Jameson, G., Ramanathan, R. K., & Von Hoff, D. D. (2017). Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. British Journal of Cancer, 117(4), 572–582. https://doi.org/10.1038/bjc.2017.209
Parkin, A., Man, J., Timpson, P., & Pajic, M. (2019). Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: From mechanism to therapy. The FEBS Journal, 286(18), 3510–3539. https://doi.org/10.1111/febs.15011
Oketch, D. J. A., Giulietti, M., & Piva, F. (2023). Copy number variations in pancreatic cancer: From biological significance to clinical utility. International Journal of Molecular Sciences, 25(1), 391. https://doi.org/10.3390/ijms25010391
Gutiérrez, M. L., Muñoz-Bellvís, L., & Orfao, A. (2021). Genomic heterogeneity of pancreatic ductal adenocarcinoma and its clinical impact. Cancers, 13(17), 4451. https://doi.org/10.3390/cancers13174451
Cortiana, V., Abbas, R. H., Chorya, H., Gambill, J., Mahendru, D., Park, C. H., & Leyfman, Y. (2024). Personalized medicine in pancreatic cancer: The promise of biomarkers and molecular targeting with Dr. Michael J. Pishvaian. Cancers, 16(13), 2329. https://doi.org/10.3390/cancers16132329
Collisson, E., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., Feiler, H. S., Ko, A. H., Olshen, A. B., Danenberg, K. L., Tempero, M. A., Spellman, P. T., Hanahan, D., & Gray, J. W. (2011). Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nature Medicine, 17(4), 500–503. https://doi.org/10.1038/nm.2344
Hyun, S., & Park, D. (2022). Challenges in genomic analysis of model systems and primary tumors of pancreatic ductal adenocarcinoma. Computational and Structural Biotechnology Journal, 20, 4806–4815. https://doi.org/10.1016/j.csbj.2022.08.064
Karamitopoulou, E. (2019). Tumour microenvironment of pancreatic cancer: Immune landscape is dictated by molecular and histopathological features. British Journal of Cancer, 121(1), 5–14. https://doi.org/10.1038/s41416-019-0479-5
Lu, S., Ahmed, T., Du, P., & Wang, Y. (2017). Genomic variations in pancreatic cancer and potential opportunities for development of new approaches for diagnosis and treatment. International Journal of Molecular Sciences, 18(6), 1201. https://doi.org/10.3390/ijms18061201
Takai, E., & Yachida, S. (2015). Genomic alterations in pancreatic cancer and their relevance to therapy. World Journal of Gastrointestinal Oncology, 7(10), 250–258. https://doi.org/10.4251/wjgo.v7.i10.250
Singhi, A. D., George, B., Greenbowe, J. R., Chung, J., Suh, J., Maitra, A., Klempner, S. J., Hendifar, A., Milind, J. M., Golan, T., Brand, R. E., Zureikat, A. H., Roy, S., Schrock, A. B., Miller, V. A., Ross, J. S., Ali, S. M., & Bahary, N. (2019). Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology, 156(8), 2242–2253. https://doi.org/10.1053/j.gastro.2019.02.037
Li, H., Di, Y., Li, J., Jiang, Y., He, H., Yao, L., Gu, J., Lu, J., Song, J., Chen, S., Cai, S., Jin, C., Yuan, Z., & Fu, D. (2020). Blood-based genomic profiling of circulating tumor DNA from patients with advanced pancreatic cancer and its value to guide clinical treatment. Journal of Cancer, 11(15), 4316–4323. https://doi.org/10.7150/jca.43087
Souza da Silva, R., Pina, M. J., Cirnes, L., Gouveia, L., Albergaria, A., & Schmitt, F. (2024). Comprehensive genomic studies on the cell blocks of pancreatic cancer. Diagnostics, 14(9), 906. https://doi.org/10.3390/diagnostics14090906
Fang, Y., Yao, Q., Chen, Z., Xiang, J., William, F. E., Gibbs, R. A., & Chen, C. (2013). Genetic and molecular alterations in pancreatic cancer: Implications for personalized medicine. Medical Science Monitor, 19, 916–926. https://doi.org/10.12659/MSM.889636
Majumder, S., Chari, S. T., & Ahlquist, D. (2015). Molecular detection of pancreatic neoplasia: Current status and future promise. World Journal of Gastroenterology, 21(40), 11387–11395. https://doi.org/10.3748/wjg.v21.i40.11387
Giannis, D., Moris, D., & Barbas, A. S. (2021). Diagnostic, predictive and prognostic molecular biomarkers in pancreatic cancer: An overview for clinicians. Cancers, 13(5), 1071. https://doi.org/10.3390/cancers13051071
Ito, T., Iwasawa, T., Sakuraba, S., & Tanaka, K. (2025). Plasma and urine circulating tumor DNA methylation profiles for non-invasive pancreatic ductal adenocarcinoma detection: Significant findings in plasma only. International Journal of Molecular Sciences, 26(11), 4972. https://doi.org/10.3390/ijms26114972
Okano, K., & Suzuki, Y. (2014). Strategies for early detection of resectable pancreatic cancer. World Journal of Gastroenterology, 20(32), 11230–11240. https://doi.org/10.3748/wjg.v20.i32.11230
Masoumi-Moghaddam, S., Lundy, J., Gao, H., Rathi, V., Swan, M., Desmond, C., Bhutani, M. S., Southey, M. C., Vaughan, R., Varma, P., Tagkalidis, P., Holt, B. A., Pilgrim, C. H., Segelov, E., Lee, B., Harris, M., Strickland, A., Frentzas, S., Zalcberg, J., ... & Croagh, D. (2021). The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial. Endoscopic Ultrasound, 10(5), 335–343. https://doi.org/10.4103/EUS-D-20-00230
Szczepanski, J. M., Rudolf, M. A., & Shi, J. (2024). Clinical evaluation of the pancreatic cancer microenvironment: Opportunities and challenges. Cancers, 16(4), 794. https://doi.org/10.3390/cancers16040794
Zhen, D. B., Safyan, R. A., Konick, E. Q., Nguyen, R., Prichard, C. C., & Chiorean, E. G. (2023). The role of molecular testing in pancreatic cancer. Therapeutic Advances in Gastroenterology, 16, 17562848231171456. https://doi.org/10.1177/17562848231171456
Jabłońska, B., & Mrowiec, S. (2023). Gastrointestinal disease: New diagnostic and therapeutic approaches. Biomedicines, 11(5), 1420. https://doi.org/10.3390/biomedicines11051420
Kozłowska, M., & Śliwińska, A. (2023). The link between diabetes, pancreatic tumors, and miRNAs-new players for diagnosis and therapy? International Journal of Molecular Sciences, 24(12), 10252. https://doi.org/10.3390/ijms241210252
Zheng, Z., Lu, Z., Yan, F., & Song, Y. (2025). The role of novel biomarkers in the early diagnosis of pancreatic cancer: A systematic review and meta-analysis. PLoS ONE, 20(5), e0322720. https://doi.org/10.1371/journal.pone.0322720
Dahiya, D. S., Malik, S., Paladiya, R., Ahsan, S., Wasim, H., Bharadwaj, H. R., Goel, A., Jaan, A., Hayat, U., Hasan, F., Sonaiya, S., & Ali, H. (2025). Advances in non-invasive screening methods for gastrointestinal cancers: How continued innovation has revolutionized early cancer detection. Cancers, 17(7), 1085. https://doi.org/10.3390/cancers17071085
Heredia-Soto, V., Rodríguez-Salas, N., & Feliu, J. (2021). Liquid biopsy in pancreatic cancer: Are we ready to apply it in the clinical practice? Cancers, 13(8), 1986. https://doi.org/10.3390/cancers13081986
Ideno, N., Mori, Y., Nakamura, M., & Ohtsuka, T. (2020). Early detection of pancreatic cancer: Role of biomarkers in pancreatic fluid samples. Diagnostics, 10(12), 1056. https://doi.org/10.3390/diagnostics10121056
Yang, J., Xu, R., Wang, C., Qiu, J., Ren, B., & You, L. (2021). Early screening and diagnosis strategies of pancreatic cancer: A comprehensive review. Cancer Communications, 41(12), 1257–1274. https://doi.org/10.1002/cac2.12204
Timmaraju, V. A., Finkelstein, S. D., & Levine, J. A. (2024). Analytical validation of loss of heterozygosity and mutation detection in pancreatic fine-needle aspirates by capillary electrophoresis and Sanger sequencing. Diagnostics, 14(5), 514. https://doi.org/10.3390/diagnostics14050514
Søreide, K., Primavesi, F., Labori, K. J., Watson, M. M., & Stättner, S. (2019). Molecular biology in pancreatic ductal adenocarcinoma: Implications for future diagnostics and therapy. European Surgery, 51, 126–134. https://doi.org/10.1007/s10353-019-0575-z

Details

Primary Language

English

Subjects

Cancer Biology, Molecular Genetics

Journal Section

Review

Authors

Şeyda Kaya ^*
0000-0001-8489-8687
Türkiye

Mustafa Murat Öztürk
0000-0002-2302-0018
Türkiye

Dilek Arslan Ateşşahin
0000-0002-1528-9367
Türkiye

İnanç Baral
0000-0001-7272-3724
Türkiye

Sevgi Durna Daştan
0009-0003-8565-6841
Türkiye

Publication Date

June 29, 2026

Submission Date

January 3, 2026

Acceptance Date

June 3, 2026

Published in Issue

Year 2026 Volume: 47 Number: 3

DOI

https://doi.org/10.17776/csj.1854954

IZ

https://izlik.org/JA39LG85JU

APA

Kaya, Ş., Öztürk, M. M., Arslan Ateşşahin, D., Baral, İ., & Durna Daştan, S. (2026). Molecular Perspective on Pancreatic Cancers with a Focus on Genetics, Genomics, and Diagnostics. Cumhuriyet Science Journal, 47(3), 427-437. https://doi.org/10.17776/csj.1854954

AMA

1.Kaya Ş, Öztürk MM, Arslan Ateşşahin D, Baral İ, Durna Daştan S. Molecular Perspective on Pancreatic Cancers with a Focus on Genetics, Genomics, and Diagnostics. CSJ. 2026;47(3):427-437. doi:10.17776/csj.1854954

Chicago

Kaya, Şeyda, Mustafa Murat Öztürk, Dilek Arslan Ateşşahin, İnanç Baral, and Sevgi Durna Daştan. 2026. “Molecular Perspective on Pancreatic Cancers With a Focus on Genetics, Genomics, and Diagnostics”. Cumhuriyet Science Journal 47 (3): 427-37. https://doi.org/10.17776/csj.1854954.

EndNote

Kaya Ş, Öztürk MM, Arslan Ateşşahin D, Baral İ, Durna Daştan S (June 1, 2026) Molecular Perspective on Pancreatic Cancers with a Focus on Genetics, Genomics, and Diagnostics. Cumhuriyet Science Journal 47 3 427–437.

IEEE

[1]Ş. Kaya, M. M. Öztürk, D. Arslan Ateşşahin, İ. Baral, and S. Durna Daştan, “Molecular Perspective on Pancreatic Cancers with a Focus on Genetics, Genomics, and Diagnostics”, CSJ, vol. 47, no. 3, pp. 427–437, June 2026, doi: 10.17776/csj.1854954.

ISNAD

Kaya, Şeyda - Öztürk, Mustafa Murat - Arslan Ateşşahin, Dilek - Baral, İnanç - Durna Daştan, Sevgi. “Molecular Perspective on Pancreatic Cancers With a Focus on Genetics, Genomics, and Diagnostics”. Cumhuriyet Science Journal 47/3 (June 1, 2026): 427-437. https://doi.org/10.17776/csj.1854954.

JAMA

1.Kaya Ş, Öztürk MM, Arslan Ateşşahin D, Baral İ, Durna Daştan S. Molecular Perspective on Pancreatic Cancers with a Focus on Genetics, Genomics, and Diagnostics. CSJ. 2026;47:427–437.

MLA

Kaya, Şeyda, et al. “Molecular Perspective on Pancreatic Cancers With a Focus on Genetics, Genomics, and Diagnostics”. Cumhuriyet Science Journal, vol. 47, no. 3, June 2026, pp. 427-3, doi:10.17776/csj.1854954.

Vancouver

1.Şeyda Kaya, Mustafa Murat Öztürk, Dilek Arslan Ateşşahin, İnanç Baral, Sevgi Durna Daştan. Molecular Perspective on Pancreatic Cancers with a Focus on Genetics, Genomics, and Diagnostics. CSJ. 2026 Jun. 1;47(3):427-3. doi:10.17776/csj.1854954

As of 2026, Cumhuriyet Science Journal will be published in six issues per year, released in February, April, June, August, October, and December

Molecular Perspective on Pancreatic Cancers with a Focus on Genetics, Genomics, and Diagnostics

Abstract

Keywords

References

Details

Primary Language

Subjects

Journal Section

Authors

Publication Date

Submission Date

Acceptance Date

Published in Issue

DOI

IZ

Cite